New data on Opdivo (nivolumab) plus Yervoy (ipilimumab)
in patients with advanced hepatocellular carcinoma and in melanoma
patients with symptomatic brain metastases

New long-term survival data and health outcomes research on Opdivo
in combination with Yervoy in advanced melanoma

Eighteen-month efficacy results for Empliciti (elotuzumab)
plus pomalidomide and low-dose dexamethasone for relapsed/refractory
multiple myeloma

Translational research exploring the use of novel technologies and
artificial intelligence to understand the association of inflammation
gene signatures with tumor immune cells

PRINCETON, N.J.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24BMY&src=ctag” target=”_blank”gt;$BMYlt;/agt; lt;a href=”https://twitter.com/hashtag/ASCO19?src=hash” target=”_blank”gt;#ASCO19lt;/agt;–Bristol-Myers
Squibb Company (NYSE:BMY) today announced the presentation of data
from across the company’s oncology portfolio at the American Society of
Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago, May 31-June 4,
and the 24^th Annual Congress of the European Hematology
Association (EHA) in Amsterdam, June 13-16. Data from over 90
Company-sponsored studies, investigator-sponsored studies and
collaborations evaluating oncology compounds and early translational
medicine across 20 types of cancer will be featured at the two meetings.
Presentations will highlight the role of Immuno-Oncology (I-O)
monotherapy and combination approaches in improving survival and quality
of life outcomes, as well as translational research investigating novel
biomarkers and diagnostics to aid in the selection of tailored
treatments for each patient based on their unique disease biology.

2019 ASCO Annual Meeting – Highlights of Bristol-Myers Squibb data
include:
*All times noted are Central Daylight Time

Hepatocellular Carcinoma

• Primary efficacy and safety results from the Phase 1/2 CheckMate -040
  study evaluating the combination of Opdivo (nivolumab) plus Yervoy
  (ipilimumab) in patients with advanced hepatocellular carcinoma,
  the most common type of liver cancer, will be presented. These data
  (Abstract #4012), including objective response rate and overall
  survival, will be featured in a poster display on Monday, June 3 from
  8-11 AM CDT, and in a poster discussion from 3-4:30 PM CDT.

Melanoma

• Safety and efficacy of Opdivo in combination with Yervoy
  in patients with symptomatic melanoma brain metastases (Abstract
  #9501) will be featured in an oral session on Tuesday, June 4, from
  9:45 AM-12:45 PM CDT.
• New long-term survival data and health outcomes research evaluating Opdivo
  in combination with Yervoy in advanced melanoma—in terms of
  survival outcomes (CA209-004, Abstract #9533), quality of life after
  four years and during the treatment-free interval following
  discontinuation of therapy (CheckMate -067, Abstracts #9551 and
  #9568), and treatment-free survival (pooled data from CheckMate -067
  and -069, Abstract # 9550) – will be featured in a poster display on
  Monday, June 3 from 1:15-4:15 PM CDT.

Renal Cell Carcinoma

• Safety and efficacy of Opdivo in combination with Yervoy
  in patients with asymptomatic advanced renal cell carcinoma brain
  metastases (Abstract #4517) will be featured in a poster display on
  Monday, June 3 from 1:15-4:15 PM CDT, and in a poster discussion from
  4:30-6 PM CDT.

Translational Medicine and Tumor Biology

• Translational data to identify potentially predictive biomarkers and
  expand translational research capabilities will be presented. Through
  the use of gene expression profiling (GEP) and machine-learning
  modeling, a novel, tumor-associated inflammation gene signature was
  identified through correlative, immunohistochemistry assessment of CD8
  expression on T cells. This CD8-derived signature was then used to
  assess inflammation of the tumor microenvironment across 12 tumor
  types (Abstract #2593). Additionally, using an innovative artificial
  intelligence-based approach, combined with T-cell localization gene
  signatures by GEP, researchers quantified the abundance of immune
  cells and their spatial location within the tumor microenvironment
  (Abstract #2594). Both abstracts will be featured in a poster session
  on Saturday, June 1 from 8-11 AM CDT.

24^th Annual Congress of the EHA – Highlights
of Bristol-Myers Squibb data include:
*All times noted are
Central European Standard Time

Multiple Myeloma

• Extended 18-month follow-up data from the Phase 2 ELOQUENT-3 trial
  (Abstract #PS1370) evaluating the addition of Empliciti (elotuzumab)
  to pomalidomide and low-dose dexamethasone in relapsed/refractory
  (R/R) multiple myeloma, including a descriptive overall survival
  analysis for the combination, will be featured in a poster session on
  Saturday, June 15 from 5:30-7 PM CEST.

Classical Hodgkin and Non-Hodgkin Lymphoma

• Updated safety and efficacy results in two patient subgroups from the
  Phase 2 CheckMate -744 study, the first risk-stratified,
  response-adapted study of Opdivo and ADCETRIS (brentuximab
  vedotin), followed by ADCETRIS and bendamustine for suboptimal
  response, in children, adolescents and young adults with R/R classical
  Hodgkin lymphoma (cHL), prior to autologous stem cell transplantation
  (Abstract #S822) will be presented in an oral presentation on
  Saturday, June 15 from 12:30-12:45 PM CEST.
• Two-year results from cohort D of the Phase 2 CheckMate -205 study,
  evaluating Opdivo plus doxorubicin, vinblastine and dacarbazine
  in patients with newly diagnosed advanced-stage cHL (Abstract #S821),
  will be presented in an oral presentation on Saturday, June 15 from
  12:15-12:30 PM CEST.
• A full analysis of the Phase 1/2 CheckMate -436 study, evaluating Opdivo
  and ADCETRIS in patients with R/R primary mediastinal large B-cell
  lymphoma (Abstract #S1601), will be presented in an oral presentation
  on Sunday, June 16 from 9-9:15 AM CEST.

2019 ASCO Annual Meeting – Company-sponsored and collaborative data
include:
*All times noted are Central Daylight Time

Gastrointestinal Malignancies

• Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients
  (pts) with advanced hepatocellular carcinoma (aHCC): Results from
  CheckMate 040
  Author: Yau
  Abstract: #4012
  Poster
  Discussion Session: Gastrointestinal (Noncolorectal) Cancer
  Monday,
  June 3, Poster Display: 8-11 AM, Hall A
  Discussion: 3-4:30 PM,
  Arie Crown Theater

• Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L)
  therapy in microsatellite instability-high/DNA mismatch repair
  deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical
  update
  Author: Lenz
  Abstract: #3521
  Poster
  Session: Gastrointestinal (Colorectal) Cancer
  Monday, June 3,
  Poster Display: 8-11 AM, Hall A

Melanoma

• Long-term follow-up of CA209-004: A phase I dose-escalation study
  of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with
  advanced melanoma
  Author: Atkins
  Abstract: #9533
  Poster
  Session: Melanoma/Skin Cancers
  Monday, June 3, Poster Display:
  1:15-4:15 PM, Hall A

• Sensitivity of treatment-free survival (TFS), a novel outcome, to
  subgroup analyses of patients (pts) with advanced melanoma (MEL)
  treated with immune checkpoint inhibitors (ICI)
  Author:
  Mantia
  Abstract: #9550
  Poster Session: Melanoma/Skin Cancers
  Monday,
  June 3, Poster Display: 1:15-4:15 PM, Hall A

• Patient-reported quality of life (QoL) of advanced melanoma
  patients in a Phase 3 study of nivolumab (NIVO) with or without
  ipilimumab (IPI) versus IPI: CheckMate 067 4-year data
  Author:
  Schadendorf
  Abstract: #9551
  Poster Session: Melanoma/Skin
  Cancers
  Monday, June 3, Poster Display: 1:15-4:15 PM, Hall A

• Quality of life (QoL) and symptom burden in patients (pts) with
  advanced melanoma during the treatment-free interval (TFI) after
  discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI)
  Author:
  Taylor
  Abstract: #9568
  Poster Session: Melanoma/Skin Cancers
  Monday,
  June 3, Poster Display: 1:15-4:15 PM, Hall A

• An analysis of nivolumab-mediated adverse events and association
  with clinical efficacy in resected stage III or IV melanoma (CheckMate
  238)
  Author: Mandala
  Abstract: #9584
  Poster
  Session: Melanoma/Skin Cancers
  Monday, June 3, Poster Display:
  1:15-4:15 PM, Hall A

• Efficacy and safety of the combination of nivolumab (NIVO) plus
  ipilimumab (IPI) in patients with symptomatic melanoma brain
  metastases (CheckMate 204)
  Author: Tawbi
  Abstract: #9501
  Oral
  Session: Melanoma/Skin Cancers
  Tuesday, June 4, 9:45 AM-12:45 PM,
  S406
  Presentation: 9:57-10:09 AM, S406

Genitourinary Malignancies

• CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or
  sunitinib in IMDC intermediate/poor-risk patients with previously
  untreated advanced renal cell carcinoma with sarcomatoid features
  Author:
  McDermott
  Abstract: #4513
  Poster Discussion Session:
  Genitourinary (Nonprostate) Cancer
  Monday, June 3, Poster
  Display: 1:15-4:15 PM, Hall A
  Discussion: 4:30-6 PM, Hall D2

• Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in
  patients with advanced renal cell carcinoma (aRCC) with brain
  metastases: Interim analysis of CheckMate 920
  Author:
  Emamekhoo
  Abstract: #4517
  Poster Discussion Session:
  Genitourinary (Nonprostate) Cancer
  Monday, June 3, Poster
  Display: 1:15-4:15 PM, Hall A
  Discussion: 4:30-6 PM, Hall D2

• Consistent efficacy of nivolumab plus ipilimumab across number of
  International Metastatic Database Consortium (IMDC) risk factors in
  CheckMate 214
  Author: Escudier
  Abstract: #4575
  Poster
  Session: Genitourinary (Nonprostate) Cancer
  Monday, June 3,
  Poster Display: 1:15-4:15 PM, Hall A

• Clinical and economic outcomes associated with sequential treatment
  in patients with advanced renal cell carcinoma (aRCC)
  Author:
  Regan
  Abstract: #4566
  Poster Session: Genitourinary
  (Nonprostate) Cancer
  Monday, June 3, Poster Display: 1:15-4:15
  PM, Hall A

• Nivolumab monotherapy in patients with advanced platinum-resistant
  urothelial carcinoma: Efficacy and safety update from CheckMate 275
  Author:
  Siefker-Radtke
  Abstract: #4524
  Poster Session: Genitourinary
  (Nonprostate) Cancer
  Monday, June 3, Poster Display: 1:15-4:15
  PM, Hall A

• Real-world outcomes with IO therapies: A prospective observational
  cohort study in patients (pts) with advanced melanoma (OPTIMIzE)
  Author:
  Kirkwood
  Abstract: #e14144
  Online Only

Translational Medicine and Biomarkers

• Serum IL-6 and CRP as prognostic factors in melanoma patients
  receiving single agent and combination checkpoint inhibition
  Author:
  Weber
  Abstract: #100
  Clinical Science Symposium: Fine-Tuning
  Checkpoint Inhibition: Biomarkers of Response and Resistance
  Saturday,
  June 1, Clinical Science Symposium: 8-9:30 AM, Hall D1
  Presentation:
  8-8:12 AM, Hall D1

• Development of a baseline prognostic cytokine signature that
  correlates with nivolumab (NIVO) clearance (CL): Translational
  pharmacokinetic/pharmacodynamic (PK/PD) analysis in patients with
  renal cell carcinoma (RCC)
  Author: Wang
  Abstract: #2544
  Poster
  Session: Developmental Immunotherapy and Tumor Immunobiology
  Saturday,
  June 1, Poster Display: 8-11 AM, Hall A

• Association of an inflammatory gene signature with CD8 expression
  by immunohistochemistry (IHC) in multiple tumor types
  Author:
  Szabo
  Abstract: #2593
  Poster Session: Developmental
  Immunotherapy and Tumor Immunobiology
  Saturday, June 1, Poster
  Display: 8-11 AM, Hall A

• CD8+ T cells in tumor parenchyma and stroma by image analysis (IA)
  and gene expression profiling (GEP): Potential biomarkers for
  immuno-oncology (I-O) therapy
  Author: Szabo
  Abstract:
  #2594
  Poster Session: Developmental Immunotherapy and Tumor
  Immunobiology
  Saturday, June 1, Poster Display: 8-11 AM, Hall A

• Association of human endogenous retrovirus (hERV) expression with
  clinical efficacy of PD-1 blockade in metastatic clear cell renal cell
  carcinoma (mccRCC)
  Author: Pignon
  Abstract: #4568
  Poster
  Session: Genitourinary (Nonprostate) Cancer
  Monday, June 3,
  Poster Display: 1:15-4:15 PM, Hall A

New and Early Assets

• Baseline tumor-immune signatures associated with response to
  bempegaldesleukin (NKTR-214) and nivolumab
  Author: Hurwitz
  Abstract:
  #2623
  Poster Session: Developmental Immunotherapy and Tumor
  Immunobiology
  Saturday, June 1, Poster Display: 8-11 AM, Hall A

• CA224-060: A randomized, open label, phase II trial of relatlimab
  (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with
  chemotherapy as first-line treatment in patients with gastric or
  gastroesophageal junction adenocarcinoma
  Author: Feeney
  Abstract:
  #TPS4143
  Poster Session: Gastrointestinal (Noncolorectal) Cancer
  Monday,
  June 3, Poster Display: 8-11 AM, Hall A

• CA045-001: A phase III, randomized, open label study of
  bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO
  monotherapy in patients (pts) with previously untreated, unresectable
  or metastatic melanoma (MEL)
  Author: Khushalani
  Abstract:
  #TPS9601
  Poster Session: Melanoma/Skin Cancers
  Monday, June
  3, Poster Display: 1:15-4:15 PM, Hall A

• A phase III randomized open label study comparing bempegaldesleukin
  (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator’s
  choice) in patients with previously untreated advanced renal cell
  carcinoma
  Author: Tannir
  Abstract: #TPS4595
  Poster
  Session: Genitourinary (Nonprostate) Cancer
  Monday, June 3,
  Poster Display: 1:15-4:15 PM, Hall A

• A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone
  or in combination with nivolumab (NIVO) ± BMS-986205 in
  cisplatin-eligible muscle invasive bladder cancer (MIBC)
  Author:
  Sonpavde
  Abstract: #TPS4587
  Poster Session: Genitourinary
  (Nonprostate) Cancer
  Monday, June 3, Poster Display: 1:15-4:15
  PM, Hall A

Clinical Collaborations

• Preliminary immunogenicity, safety, and efficacy of JNJ-64041757
  (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two
  phase 1 studies
  Author: Brahmer
  Abstract: #9093
  Poster
  Session: Lung Cancer-Non-Small Cell Metastatic
  Sunday, June 2,
  Poster Display: 8-11 AM, Hall A

• An open label, multicenter, phase I/II study of RP1 as a single
  agent and in combination with PD1 blockade in patients with solid
  tumors
  Author: Middleton
  Abstract: #TPS2671
  Poster
  Session: Developmental Immunotherapy and Tumor Immunobiology
  Saturday,
  June 1, Poster Display: 8-11 AM, Hall A

• Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ±
  ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC
  Author:
  Malhotra
  Abstract: #8516
  Poster Session: Lung
  Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
  Sunday,
  June 2, Poster Display: 8-11 AM; Hall A
  Discussion: 11:15
  AM–12:45 PM, S406

24^th Congress of the EHA – Company-sponsored
and collaborative data include:
*All times noted are Central
European Summer Time

Lymphoma

• Nivolumab Plus Doxorubicin, Vinblastine and Dacarbazine for Newly
  Diagnosed Advanced-Stage Classical Hodgkin Lymphoma: 2-Year Extended
  Follow-Up From Cohort D of the Phase 2 CheckMate 205 Study
  Author:
  Domingo-Domènech
  Abstract: #S821
  Oral Session: Hodgkin
  lymphoma – Clinical
  Saturday, June 15, 11:30 AM-12:45 PM, Hall 5
  Presentation:
  12:15-12:30 PM, Hall 5

• Nivolumab and Brentuximab Vedotin-Based, Response-Adapted Treatment
  in Primary Refractory and in Pediatric Patients with
  Relapsed/Refractory Classical Hodgkin Lymphoma in CheckMate 744
  Author:
  LeBlanc
  Abstract: #S822
  Oral Session: Hodgkin lymphoma –
  Clinical
  Saturday, June 15, 11:30 AM-12:45 PM, Hall 5
  Presentation:
  12:30-12:45 PM, Hall 5

• Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory
  Primary Mediastinal Large B-cell Lymphoma: Efficacy and Safety Results
  from the Phase 2 CheckMate 436 Study
  Author: Zinzani
  Abstract:
  #S1601
  Oral Session: Aggressive lymphomas – First line,
  combination therapy and real-life data
  Sunday, June 16, 8-9:15
  AM, Hall 5
  Presentation: 9-9:15 AM, Hall 5

Multiple Myeloma

• Elotuzumab Plus Pomalidomide and Dexamethasone for
  Relapsed/Refractory Multiple Myeloma: Efficacy Results After
  Additional Follow-Up of the Phase 2, Randomized ELOQUENT-3 Study
  Author:
  Dimopoulos
  Abstract: #PS1370
  Poster Session: Myeloma and
  other monoclonal gammopathies – Clinical
  Saturday, June 15,
  5:30-7 PM, Poster Area

• Investigating Mechanisms of Elotuzumab and Lenalidomide in Multiple
  Myeloma
  Author: Richardson
  Abstract: #PF568
  Poster
  Session: Myeloma and other monoclonal gammopathies – Biology &
  Translational Research
  Friday, June 14, 5:30-7 PM, Poster Area

• Use of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple
  Myeloma in Four European Countries – Findings From PREAMBLE
  Author:
  Moreau
  Abstract: #PS1405
  Poster Session: Myeloma and other
  monoclonal gammopathies – Clinical
  Saturday, June 15, 5:30-7 PM,
  Poster Area

Leukemia

• DASCERN 2-Year Extended Follow-Up of Dasatinib Efficacy and Safety
  in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase
  (CML-CP) Who Have Suboptimal Responses to 3 Months of Imatinib
  Author:
  Saglio
  Abstract: #PF405
  Poster Session: Chronic myeloid
  leukemia – Clinical
  Friday, June 14, 5:30-7 PM, Poster Area

• DASFREE: 2-Year Update: Dasatinib Discontinuation in Patients (pts)
  with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep
  Molecular Response (DMR)
  Author: Shah
  Abstract: #PF408
  Poster
  Session: Chronic myeloid leukemia – Clinical
  Friday, June 14,
  5:30-7 PM, Poster Area

• Growth Rate and Endocrine Effects of Dasatinib Therapy Observed in
  Retrospective Analysis of a Phase II Clinical Trial for Pediatric
  Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
  Author:
  Patterson
  Abstract: #PF416
  Poster Session: Chronic myeloid
  leukemia – Clinical
  Friday, June 14, 5:30-7 PM, Poster Area

• Dosing Patterns of Dasatinib and Nilotinib Use in SIMPLICITY, an
  Observational Study in Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
  Patients (pts) in Routine Clinical Practice
  Author: Cortes
  Abstract:
  #PS1181
  Poster Session: Chronic myeloid leukemia – Clinical
  Saturday,
  June 15, 5:30-7 PM, Poster Area

Bristol-Myers Squibb: Advancing Oncology
Research

At Bristol-Myers Squibb, patients are at the center of everything we do.
The focus of our research is to increase quality, long-term survival for
patients and make cure a possibility. Through a unique multidisciplinary
approach powered by translational science, we harness our deep
scientific experience in oncology and Immuno-Oncology (I-O) research to
identify novel treatments tailored to individual patient needs. Our
researchers are developing a diverse, purposefully built pipeline
designed to target different immune system pathways and address the
complex and specific interactions between the tumor, its
microenvironment and the immune system. We source innovation internally,
and in collaboration with academia, government, advocacy groups and
biotechnology companies, to help make the promise of transformational
medicines, like I-O, a reality for patients.

About Opdivo

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor
that is designed to uniquely harness the body’s own immune system to
help restore anti-tumor immune response. By harnessing the body’s own
immune system to fight cancer, Opdivo has become an
important treatment option across multiple cancers.

Opdivo’s leading global development program is based on
Bristol-Myers Squibb’s scientific expertise in the field of
Immuno-Oncology, and includes a broad range of clinical trials across
all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical
development program has treated more than 35,000 patients. The Opdivo trials
have contributed to gaining a deeper understanding of the potential role
of biomarkers in patient care, particularly regarding how patients may
benefit from Opdivo across the continuum of PD-L1 expression.

In July 2014, Opdivo was the first PD-1 immune checkpoint
inhibitor to receive regulatory approval anywhere in the world. Opdivo is
currently approved in more than 65 countries, including the United
States, the European Union, Japan and China. In October 2015, the
Company’s Opdivo and Yervoy combination regimen was the
first Immuno-Oncology combination to receive regulatory approval for the
treatment of metastatic melanoma and is currently approved in more than
50 countries, including the United States and the European Union.

U.S. FDA-APPROVED INDICATIONS FOR OPDIVO^®

OPDIVO^® (nivolumab) as a single agent is indicated for the
treatment of patients with unresectable or metastatic melanoma.

OPDIVO^® (nivolumab), in combination with YERVOY^®
(ipilimumab), is indicated for the treatment of patients with
unresectable or metastatic melanoma.

OPDIVO^® (nivolumab) is indicated for the treatment of
patients with metastatic non-small cell lung cancer (NSCLC) with
progression on or after platinum-based chemotherapy. Patients with EGFR
or ALK genomic tumor aberrations should have disease progression on
FDA-approved therapy for these aberrations prior to receiving OPDIVO.

OPDIVO^® (nivolumab) is indicated for the treatment of
patients with metastatic small cell lung cancer (SCLC) with progression
after platinum-based chemotherapy and at least one other line of
therapy. This indication is approved under accelerated approval based on
overall response rate and duration of response. Continued approval for
this indication may be contingent upon verification and description of
clinical benefit in confirmatory trials.

OPDIVO^® (nivolumab) is indicated for the treatment of
patients with advanced renal cell carcinoma (RCC) who have received
prior anti-angiogenic therapy.

OPDIVO^® (nivolumab), in combination with YERVOY^®
(ipilimumab), is indicated for the treatment of patients with
intermediate or poor risk, previously untreated advanced renal cell
carcinoma (RCC).

OPDIVO^® (nivolumab) is indicated for the treatment of adult
patients with classical Hodgkin lymphoma (cHL) that has relapsed or
progressed after autologous hematopoietic stem cell transplantation
(HSCT) and brentuximab vedotin or after 3 or more lines of systemic
therapy that includes autologous HSCT. This indication is approved under
accelerated approval based on overall response rate. Continued approval
for this indication may be contingent upon verification and description
of clinical benefit in confirmatory trials.

OPDIVO^® (nivolumab) is indicated for the treatment of
patients with recurrent or metastatic squamous cell carcinoma of the
head and neck (SCCHN) with disease progression on or after
platinum-based therapy.

OPDIVO^® (nivolumab) is indicated for the treatment of
patients with locally advanced or metastatic urothelial carcinoma who
have disease progression during or following platinum-containing
chemotherapy or have disease progression within 12 months of neoadjuvant
or adjuvant treatment with platinum-containing chemotherapy. This
indication is approved under accelerated approval based on tumor
response rate and duration of response. Continued approval for this
indication may be contingent upon verification and description of
clinical benefit in confirmatory trials.

OPDIVO^® (nivolumab), as a single agent, is indicated for the
treatment of adult and pediatric (12 years and older) patients with
microsatellite instability-high (MSI-H) or mismatch repair deficient
(dMMR) metastatic colorectal cancer (CRC) that has progressed following
treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This
indication is approved under accelerated approval based on overall
response rate and duration of response. Continued approval for this
indication may be contingent upon verification and description of
clinical benefit in confirmatory trials.

Contacts

Bristol-Myers Squibb Company
Media Inquiries:
Ken
Dominski
609-302-3114
ken.dominski@bms.com

Investors:
Tim Power
609-252-7509
timothy.power@bms.com

Read full story here